• About us
    • Profile
    • Board of Directors
    • Scientific Directors
  • Our Science
    • Strategy
    • Activities and Technologies
  • Pipeline
    • Pipeline
    • OncoFAP-Radio Conjugates
    • OncoFAP-Drug Conjugate
    • Onco IX (PHC-102, Imaging)
  • Press releases & Events
  • Work with us
    • Careers
    • Industrial Ph.D. Program
    • Partnering
  • About us
    • Profile
    • Board of Directors
    • Scientific Directors
  • Our Science
    • Strategy
    • Activities and Technologies
  • Pipeline
    • Pipeline
    • Onco IX (PHC-102, Imaging)
    • OncoFAP-Radio Conjugates
    • OncoFAP-Drug Conjugate
  • Press releases & Events
  • Work with us
    • Careers
    • Industrial Ph.D. Program
    • Partnering

Philogen announces publication of best-in-class FAP-targeting small molecule ligand (OncoFAP) in PNAS

by last | May 4, 2021 | 2021, Press Releases, Scientific

Study shows impressive tumor uptake of OncoFAP with unprecedented selectivity against healthy organs. OncoFAP-based molecules are currently being developed for the imaging and therapy of cancer. Philogen announces participation to the 10th World Congress of Melanoma...

Philogen announces the completion of a second interim analysis of its phase III clinical program with NidlegyTM for the treatment of melanoma

by last | Jan 13, 2021 | 2021, Press Releases, Scientific

NidlegyTMwas found to be well-tolerated and 149 out of the anticipated 214 patients have been safely treated. Data Safety Monitoring Board recommends to continue the study as planned. PRESS RELEASE – 13/01/2021  

Philogen announced Option and License Agreement with Pfizer Inc.

by last | Dec 22, 2014 | 2014, Press Releases, Scientific

Philogen announced Option and License Agreement with Pfizer Inc. to develop and commercialize multiple antibody drug conjugates and targeted nano particles. (see full press release). Siena (Italy), December 22nd, 2014.

Dario Neri – presented ‘Immunocytokines for the therapy of cancer and of chronic inflammation’ at Antibody Engineering and Therapeutics conference

by last | Dec 7, 2014 | 2014, Press Releases, Scientific

Dario Neri – presented ‘Immunocytokines for the therapy of cancer and of chronic inflammation’ at Antibody Engineering and Therapeutics conference. Huntingdon Beach, California (USA), December 7th-11th, 2014.
Next Entries »

Recent Posts

  • Philogen announces new publication in Nature Chemistry
  • Philochem to attend the 71st American Society for Mass Spectrometry Conference on June 4-8, 2023
  • Philogen to attend AACR Annual Meeting in Orlando on April 14-18, 2023
  • Philogen to attend Mid & Small | London 2023 Conference on April 20, 2023
  • Philogen to attend 19th EADO Congress on April 20-22, 2023

Recent Comments

    Philochem AG ©

    Privacy / Contacts

    • Follow

    Philochem AG | Libernstrasse 3 | CH-8112 | Otelfingen – Switzerand |MWST-Nr/VAT-REG: CHE-113.181.443 | Registration Nr. CH-020.3.030.226-7 Ph. (+41) 43 544 88 00 | Fax (+41) 43 544 88 09| info@philochem.ch